SecBot SecBot

CLDI

Calidi Biotherapeutics, Inc.
OTC· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001855485 Biotech & Drug Discovery
$0.6450 −0.00 (−0.77%)
Oct 23 4:00 PM ET · prev $0.6500
Market cap
$2.4M
Nano cap
1 year
−97.4%
from $24.64 · Oct 24
30 days
−46.3%
from $1.20
52-week range
$0.6450–26.56
at the low
Avg volume 20D
54.7K
Oct 22 spike 201.1K
Short interest
233.3K
≈6.3% of shares · +2.4%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 3 bearish · 0 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 3/5
Strongest BEARISH Calidi Biotherapeutics received a delisting notice from NYSE American on September 21, 2026, for failing to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 5 added (0 new), 0 trimmed or exited.

  • Short sellersSTEADY

    Short interest +2.4% to 233.3K shares. 1.0 days to cover, ≈6.3% of shares.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $0.6450 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD114,550$19.5K
JANE STREET GROUP, LLCADD54,274$9.2K
MORGAN STANLEYADD13,244$2.3K
CITIGROUP INCDOUBLED4,594$781.00
OSAIC HOLDINGS, INC.ADD2,650$450.00
GEODE CAPITAL MANAGEMENT, LLCADD63,019$15.0K
JANE STREET GROUP, LLCDOUBLED34,802$8.3K
MORGAN STANLEYDOUBLED9,467$2.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2024
Recent actions
DateFirmActionRating
Jun 27, 2024Ladenburg Thalmann
INITIATE
INITIATEBuy
May 15, 2024Baird
MAINTAIN
MAINTAINOutperform
Mar 21, 2024Baird
MAINTAIN
MAINTAINOutperform
Mar 21, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 22, 2023HC Wainwright & Co.
INITIATE
INITIATEBuy
Oct 9, 2023Baird
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 17, 2026
Stewart Alan R.
Director
AWARD4,000 sh
Aug 17, 2026
Peoples George
Director
AWARD4,000 sh
Aug 17, 2026
Leftwich Scott
Director
AWARD4,000 sh
Aug 17, 2026
Jackson Andrew C.
Chief Financial Officer
AWARD14,000 sh
Aug 17, 2026
Schoeneck James A
Director
AWARD5,000 sh
Aug 17, 2026
Poma Eric E
Chief Executive Officer
AWARD32,000 sh
Aug 17, 2026
Fernandez Santidrian Antonio
Chief Scientific Officer
AWARD16,000 sh
Aug 17, 2026
Sanders Corazon (Corsee) D.
Director
AWARD6,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
233,287
shares short
+2.4%
vs prior settlement
1.0
days to cover
≈6.3%
of shares outstanding
Trading halts
Jul 29, 2026Resumption ScheduledResumed
Jul 29, 2026Regulatory ConcernNot resumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Other
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Ca
Sep 25, 2026 SEC
Calidi Biotherapeutics received a delisting notice from NYSE American on September 21, 2026, for failing to meet the…
8-K — Impact 7/10
Sep 22, 2026 SEC
Calidi Biotherapeutics entered into a stock purchase agreement for a registered direct offering of 1,025,640 shares at…
8-K — Impact 6/10
Sep 17, 2026 SEC
Calidi Biotherapeutics is issuing 1,025,640 shares of common stock at $1.17 per share in a direct offering to…
424B5 — Impact 6/10
Aug 17, 2026 Insider
Stewart Alan R. was granted 4,000 shares
Director
Aug 17, 2026 Insider
Peoples George was granted 4,000 shares
Director
Aug 17, 2026 Insider
Leftwich Scott was granted 4,000 shares
Director
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
114,550 shares ($19.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 19, 2026
Press release
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology…
Sep 25, 2026
Press release
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology…
Sep 17, 2026
Press release
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology…
Sep 8, 2026
Press release
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company…
Aug 13, 2026
Earnings
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human…

SecBot reports

6 filings · 6 press releases · 0 bullish · 3 bearish · 2 mixed · 1 neutral
All CLDI filing & press-release reports (12)